At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ODD ODDITY Tech Ltd.
Market Closed 01-09 16:00:00 EST
35.42
-3.09
-8.02%
盘后36.06
+0.64+1.81%
19:54 EST
High38.97Low35.32Vol1.82M
Open38.96D1 Closing38.51Amplitude9.48%
Mkt Cap2.03BTradable Cap1.37BTotal Shares57.44M
T/O65.50MT/O Rate4.70%Tradable Shares38.70M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Is It Time To Reassess Oddity Tech (ODD) After Recent Share Price Weakness?
Simply Wall St.  ·  01-08 22:40
Is It Time To Reassess Oddity Tech (ODD) After Recent Share Price Weakness?
ODDITY Tech Is Maintained at Overweight by Keybanc
Dow Jones  ·  01-08 22:29
ODDITY Tech Is Maintained at Overweight by Keybanc
KeyBanc Reaffirms Their Buy Rating on ODDITY Tech Ltd. Class A (ODD)
TIPRANKS  ·  01-08 19:16
KeyBanc Reaffirms Their Buy Rating on ODDITY Tech Ltd. Class A (ODD)
Oddity Tech Ltd. Chief Science Officer Departs
Reuters  ·  01-08 05:26
Oddity Tech Ltd. Chief Science Officer Departs
Highlighting December 2025's Growth Leaders With Insider Ownership
Simply Wall St.  ·  2025-12-16
Highlighting December 2025's Growth Leaders With Insider Ownership
ODDITY Tech Is Maintained at Overweight by JP Morgan
Dow Jones  ·  2025-12-13
ODDITY Tech Is Maintained at Overweight by JP Morgan
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
GlobeNewswire  ·  2025-12-11
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
GlobeNewswire  ·  2025-12-11
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
GlobeNewswire  ·  2025-12-09
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire  ·  2025-12-08
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
GlobeNewswire  ·  2025-12-08
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Cboe to Offer Nearly 24-Hour Trading for Russell 2000 Options, Expanding Global Access to U.S. Small-Cap Equities
prnewswire  ·  2025-12-03
Cboe to Offer Nearly 24-Hour Trading for Russell 2000 Options, Expanding Global Access to U.S. Small-Cap Equities
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
GlobeNewswire  ·  2025-11-25
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Oddity Tech's Methodiq Telehealth Platform to be Key Driver for Stock Going Ahead, Morgan Stanley Says
MT Newswires Live  ·  2025-11-21
Oddity Tech's Methodiq Telehealth Platform to be Key Driver for Stock Going Ahead, Morgan Stanley Says
Stock Track | ODDITY Tech Plummets 5.21% as Multiple Analysts Slash Price Targets
Stock Track  ·  2025-11-21
Stock Track | ODDITY Tech Plummets 5.21% as Multiple Analysts Slash Price Targets
Stock Track | ODDITY Tech Plummets 5.21% as Multiple Analysts Slash Price Targets
Stock Track  ·  2025-11-21
Stock Track | ODDITY Tech Plummets 5.21% as Multiple Analysts Slash Price Targets
ODDITY Tech Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones  ·  2025-11-21
ODDITY Tech Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Lowers Price Target on ODDITY Tech to $49 From $61, Keeps Equalweight Rating
MT Newswires Live  ·  2025-11-21
Morgan Stanley Lowers Price Target on ODDITY Tech to $49 From $61, Keeps Equalweight Rating
Bath & Body Works, Inc. : Morgan Stanley Cuts to Equal-Weight From Overweight
THOMSON REUTERS  ·  2025-11-21
Bath & Body Works, Inc. : Morgan Stanley Cuts to Equal-Weight From Overweight
Bath & Body Works, Inc. : Morgan Stanley Cuts Target Price to $18.00 From $43.00
THOMSON REUTERS  ·  2025-11-21
Bath & Body Works, Inc. : Morgan Stanley Cuts Target Price to $18.00 From $43.00

Introduction

Company Name.
ODDITY Tech Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.
Issue price:
--